Intelligent Bio Solutions Reports 98% Accuracy in Latest Drug Screening Study
NEW YORK, Sept. 01, 2026 /CourierPR/ -- Intelligent Bio Solutions Inc. (Nasdaq: INBS), a leading medical technology company, has announced groundbreaking results from its latest Method Comparison Study for the Intelligent Fingerprinting Drug Screening System. The study, conducted across three independent U.S. clinical sites, demonstrated the system's enhanced accuracy and reliability, marking a significant step forward in the company's regulatory pathway.
The Intelligent Fingerprinting Drug Screening System was evaluated for its ability to detect the opiate codeine. The study showed an accuracy rate above 98%, with sensitivity at 94% and a 100% specificity rate. These findings represent a notable improvement from the company's previous study, which reported approximately 94% accuracy and 82% sensitivity. The system's consistent 100% specificity underscores its ability to correctly identify samples without the target drug, a critical aspect for workplace drug testing applications.
Harry Simeonidis, President and CEO of Intelligent Bio Solutions, commented, "These results have been a long time in the making. Our System was already delivering 100% specificity, but we knew we needed to enhance sensitivity. Moving from around 82% sensitivity to above 94%, and consequently increasing overall accuracy to above 98%, is the outcome we were working toward. With this study complete, we now have all the data we need for our 510(k) submission, which remains on track for submission in September 2026."
The results of this study form a crucial part of the company's 510(k) submission package. With all data collection now complete, Intelligent Bio Solutions Inc. has accelerated its filing timeline. The company is poised to submit its 510(k) application, supporting its planned entry into the U.S. market following FDA clearance.
Intelligent Bio Solutions Inc. designs its Intelligent Fingerprinting Drug Screening System as a hygienic and cost-effective solution, ideal for safety-critical industries. The test can screen for commonly used drugs in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology has the potential to revolutionize portable drug testing.
The company's customer segments outside the U.S. include construction, manufacturing and engineering firms, transport and logistics firms, mining operations, drug treatment organizations, and coroners. Intelligent Bio Solutions Inc. remains committed to expanding its reach and ensuring that its technology is available to a wide range of organizations.
The announcement reflects the company's progress toward regulatory approval and highlights its commitment to delivering reliable, non-invasive drug screening solutions. With the 510(k) submission set for September 2026, Intelligent Bio Solutions Inc. is on course to enter the U.S. market with a robust product that meets the stringent requirements of workplace drug testing.